Newcastle biotech CellRev, which developed enzymatic processes for cultured meat and tissue engineering, has gone into administration, resulting in nine redundancies. The company, spun out of Newcastle University in 2018, aimed to advance lab-grown meat production and accelerate tissue-based therapies.
Over its life, CellRev raised multiple funding rounds: £1.2m in 2021 from CPT Capital, Northstar Ventures, and the Northern Accelerator Seed Investment Fund; £1.75m in 2022 led by Happiness Capital and Allusion One; and £1.4m in 2023 through North East Innovation Fund, European Regional Development Fund support, CPT Capital, and Innovate UK grants.
CellRev also partnered with BSF Enterprise to launch Cultivated Meat Technologies Limited, targeting scalable production and industry licensing. BSF withdrew from the venture in late 2024, retaining full ownership.
Administrators from Armstrong Watson were appointed on 12 August 2025. All staff have been made redundant. The administrators are working with Hilco Valuation Services to manage and realise the company’s assets.